5 Metrics Every Clinical Supply Leader Should Report to the Board

Most clinical supply reporting fails upward. The metrics that a supply team lives by — resupply triggers, shipment counts, depot inventory levels — are operationally vital and almost entirely meaningless to a board. Present them to executives and you get polite nods and no engagement, right up until something goes wrong and the board suddenly wants to know why they never saw it coming.

The problem isn't that supply chains lack good metrics. It's that board-level reporting requires translation — turning operational data into the language a board actually thinks in: risk to the timeline, risk to the budget, risk to patients, and risk to compliance. Here are the five metrics that make that translation, and why each earns its place in front of leadership.

1. Supply risk to key milestones

What it answers: Is the supply chain going to threaten a milestone the business cares about — a database lock, an interim analysis, a readout, a launch?

This is the single most important thing a board needs from supply, because milestones are the currency executives and investors run on. A slipped readout has consequences that ripple through funding, partnerships, and strategy. Reporting supply as a red/amber/green risk against each key milestone — with the specific driver behind any amber or red — translates the entire function into terms the board already prioritizes. Every other metric is, in a sense, a component of this one.

2. Patient supply coverage (service level)

What it answers: Is there a risk that a patient won't have their treatment when they need it?

Boards care about patients — for ethical reasons, for data-integrity reasons, and because a supply-driven dosing failure is a reputational and regulatory event. Rather than raw inventory numbers, report the risk of a patient missing a dose: are any sites or countries trending toward a coverage gap, and what's being done about it. This reframes inventory from an operational detail into a patient-and-data risk the board can weigh.

3. Projected cost and waste efficiency

What it answers: How much of what we're spending on supply is protecting the trial, and how much is being destroyed?

Supply is a major cost center, and much of its waste is invisible unless someone surfaces it. Reporting projected end-of-trial waste — the share of drug likely to be destroyed — alongside supply cost gives the board a lever they didn't know they had. It also creates the right incentive: a function that only ever reports stockouts will always over-supply, because nobody's watching the waste. Put waste in front of the board and it stops being free. This metric turns supply from a cost the board tolerates into one they can actually influence.

4. Quality and cold chain performance

What it answers: Are we in control of product quality and compliance, or accumulating risk?

Boards need a clear read on whether quality is under control, without drowning in excursion logs. A concise measure — excursion frequency and, crucially, how excursions were dispositioned and prevented — tells the board whether the operation is managing quality well or quietly building exposure. The emphasis matters: it's not "zero excursions" (unrealistic), it's evidence that excursions are being detected, contained, and prevented. That's a signal of organizational control, which is exactly what a board should want to see.

5. Forecast confidence

What it answers: How much should we trust the supply plan these other numbers rest on?

This is the most overlooked board metric, and arguably the most sophisticated. Every projection above depends on a demand forecast, and forecasts carry uncertainty. Reporting the confidence in the forecast — how well actual enrollment and demand are tracking the assumptions, and how much variance the plan can absorb — tells the board how much weight to put on everything else. A green milestone built on a forecast that's diverging from reality is a warning the board deserves to see before it turns red. Forecast confidence is the metric that keeps the other four honest.

The principle underneath all five

Notice what these five share: not one of them is an operational statistic. Each translates the supply chain into a business consequence — timeline, patients, cost, compliance, and confidence. That's the discipline of board reporting. The operational metrics still matter enormously; they're just the inputs, not the output. The board doesn't need to see how the supply chain runs. It needs to know what the supply chain means for the things the board is accountable for.

Get this right and something valuable happens: supply chain stops being the function nobody thinks about until it fails, and becomes a source of intelligence the board actually uses.